UPDATE 2-Dexcom forecasts 2025 revenue largely in-line with expectations

Adds CEO quote and details on company's expectation in paragraphs 3 to 5, analyst quote in paragraph 8

By Christy Santhosh

Jan 13 (Reuters) - Dexcom DXCM.O forecast total annual revenue largely in line with Wall Street expectations on Monday, on bets there will be strong demand for its continuous glucose monitors for diabetes patients, sending the medical device maker's shares up nearly 6% premarket.

Dexcom's shares had fallen nearly 37% last year, largely due to a slump in July after the company slashed its annual revenue forecast, blaming a restructuring of its sales team, fewer customers and lower revenue.

The California-based device maker is pinning its hopes on its recently launched device Stelo for adults aged 18 and older who do not use insulin, making it the first continuous glucose monitor available for over-the-counter sales.

"Dexcom made key strategic investments in 2024," said CEO Kevin Sayer, adding the company plans to build on these investments in 2025 by advocating for greater CGM access globally.

The company is counting on further international expansion to drive growth after it said it improved access to its devices in markets such as Japan and France last quarter.

The medical device maker expects annual revenue of $4.60 billion in 2025, compared with analysts' estimates of $4.61 billion.

It reported preliminary fourth-quarter revenue of at least $1.11 billion, compared with analysts' estimates of $1.10 billion according to data compiled by LSEG.

Dexcom's outperformance in the fourth quarter was likely enough to signal a continued recovery in the business and good performance into 2025, J.P.Morgan analyst Robbie Marcus wrote in a note.

(Reporting by Christy Santhosh in Bengaluru; Editing by Krishna Chandra Eluri)

((Christy.Santhosh@thomsonreuters.com;))